• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Other Diseases
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Other Diseases
    • View Item
    Apr 22, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Research Priorities to Achieve Universal Access to Hepatitis C Prevention, Management and Direct-Acting Antiviral Treatment Among People Who Inject Drugs

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Grebely, J
    Bruneau, J
    Lazarus, J
    Dalgard, O
    Bruggmann, P
    Treloar, C
    Hickman, M
    Hellard, M
    Roberts, T
    Crooks, L
    Midgard, H
    Larney, S
    Degenhardt, L
    Alho, H
    Byrne, J
    Dillon, J
    Feld, J
    Foster, G
    Goldberg, D
    Lloyd, A
    Reimer, J
    Robaeys, G
    Torrens, M
    Wright, N
    Maremmani, I
    Norton, B
    Litwin, A
    Dore, G
    Show allShow less
    Issue Date
    2017-07-03
    Submitted date
    2017-07-11
    
    Metadata
    Show full item record
    Journal
    The International Journal on Drug Policy
    Abstract
    Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of HCV infection among current PWID also remains high in many settings. Morbidity and mortality due to liver disease among PWID with HCV infection continues to increase, despite the advent of well-tolerated, simple interferon-free direct-acting antiviral (DAA) HCV regimens with cure rates >95%. As a result of this important clinical breakthrough, there is potential to reverse the rising burden of advanced liver disease with increased treatment and strive for HCV elimination among PWID. Unfortunately, there are many gaps in knowledge that represent barriers to effective prevention and management of HCV among PWID. The Kirby Institute, UNSW Sydney and the International Network on Hepatitis in Substance Users (INHSU) established an expert round table panel to assess current research gaps and establish future research priorities for the prevention and management of HCV among PWID. This round table consisted of a one-day workshop held on 6 September, 2016, in Oslo, Norway, prior to the International Symposium on Hepatitis in Substance Users (INHSU 2016). International experts in drug and alcohol, infectious diseases, and hepatology were brought together to discuss the available scientific evidence, gaps in research, and develop research priorities. Topics for discussion included the epidemiology of injecting drug use, HCV, and HIV among PWID, HCV prevention, HCV testing, linkage to HCV care and treatment, DAA treatment for HCV infection, and reinfection following successful treatment. This paper highlights the outcomes of the roundtable discussion focused on future research priorities for enhancing HCV prevention, testing, linkage to care and DAA treatment for PWID as we strive for global elimination of HCV infection.
    Publisher
    Elsevier
    URI
    http://hdl.handle.net/10144/619009
    DOI
    10.1016/j.drugpo.2017.05.019
    PubMed ID
    28683982
    Language
    en
    Description
    We regret that this article is behind a paywall.
    ISSN
    1873-4758
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.drugpo.2017.05.019
    Scopus Count
    Collections
    Other Diseases

    entitlement

    Related articles

    • Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    • Authors: Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, McLean E, Trooskin S, Treloar C, Grebely J
    • Issue date: 2019 Apr
    • Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    • Authors: Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ, International Network for Hepatitis in Substance Users.
    • Issue date: 2015 Oct
    • Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    • Authors: Bruggmann P, Grebely J
    • Issue date: 2015 Feb
    • Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
    • Authors: Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C, International Network on Hepatitis in Substance Users.
    • Issue date: 2019 Oct
    • Direct-acting antiviral agents for HCV infection affecting people who inject drugs.
    • Authors: Grebely J, Hajarizadeh B, Dore GJ
    • Issue date: 2017 Nov
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.